Experimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agent

Autor: M. Kontogiorgi, D. Dimitroulopoulos, I. Tsiolis, L. Papadimitriou, I. Papadimitriou, I. Vassiliou, E. Felekouras, E Lykoudis, I. Loukopoulos, I. Sfiniadakis, E. Theodossopoulou, A. Chairakakis, A. Papalois, A. Gravvanis, P. Dedeilias
Rok vydání: 2005
Předmět:
Interleukin 2
Male
Transplantation
Homologous/*immunology
Hepatocytes/*cytology/*transplantation
Daclizumab
Liver Failure
Acute/*surgery
medicine.drug_class
medicine.medical_treatment
Antibodies
Monoclonal/*therapeutic use
Pharmacology
Monoclonal antibody
Antibodies
Monoclonal
Humanized
medicine
Animals
Transplantation
Homologous
IL-2 receptor
Rats
Wistar
Immunoglobulin G/*therapeutic use
Transplantation
geography
geography.geographical_feature_category
biology
business.industry
Graft Survival
Antibodies
Monoclonal
Receptors
Interleukin-2
Liver Failure
Acute
Receptors
Interleukin-2/immunology
Islet
Immunosuppressive Agents/*therapeutic use
Rats
Rats
Inbred Lew
Immunoglobulin G
Immunology
Models
Animal
biology.protein
Hepatocytes
Surgery
Antibody
business
Immunosuppressive Agents
Spleen
medicine.drug
Allotransplantation
Zdroj: Transplantation proceedings. 37(4)
ISSN: 0041-1345
Popis: INTRODUCTION: Daclizumab (Dmab) is a genetically engineered humanized IgG1 monoclonal antibody that binds to the alpha chain of the interleukin-2 receptor (Tac, CD25, p55) expressed on activated human T lymphocytes. Dmab has been used in a clinical protocol of islet transplantation with satisfactory results. The aim of the present study was to evaluate the use of an antibody against the interleukin-2 receptor (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte allotransplantation (allo-Tx) in rats with fulminant hepatic failure (FHF). MATERIALS AND METHODS: Six Wistar rats were used as donors and 48 Lewis rats as recipients: four groups of 12 animals each with induction of FHF and 24 hour later hepatocyte Tx--group A: no treatment; group B: cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C: Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and cyclosporine. Hepatocytes were transplanted intrasplenically. Animals were followed for 15 days. RESULTS: Statistical analysis showed better survival among groups C (83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72, MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not significantly than group C. Biochemical evaluation and histology confirmed satisfactory function and engraftment, respectively. CONCLUSION: This experimental model showed the safe, effective use of Dmab. Transplant Proc
Databáze: OpenAIRE
Externí odkaz: